Select your country

Africa
Asia
Europe
Latin America
North America
Oceania

Merck KGaA, Darmstadt, Germany, Announces Collaborations and Investment in all Three Business Sectors in China

Merck KGaA, Darmstadt, Germany today announced today announced moves designed to pave the way for an even more successful future in China.

20 Jun 2018 | Darmstadt, Germany
  • Partnership with Alibaba Health
  • Investment in OLED Technology Center China
  • Cooperation with Tongji University
  • Anniversary celebration in Shanghai with key stakeholders

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced today announced moves designed to pave the way for an even more successful future in China. During the ceremony marking the company’s 350th anniversary, Merck KGaA, Darmstadt, Germany, signed an agreement with Alibaba Health, opened a technology center for its OLED customers in Shanghai, and announced the participation of Tongji University, Shanghai, China, in its CRISPR Core Partnership program.

Stefan Oschmann, Chairman of the Executive Board and CEO of Merck KGaA, Darmstadt Germany, welcomed 400 guests representing the worlds of politics, business and society to the company’s 350th anniversary celebration in Shanghai. “As we mark our 350th anniversary, we are curiously looking towards the future – and to a large extent, the future of science and technology will be shaped here in China. With today’s news we are strengthening our footprint in this vibrant ecosystem of innovation. Together with our Chinese partners, we want to create technologies that make a meaningful difference in the lives of people in China and around the globe,” Stefan Oschmann said on Wednesday.

The new collaboration with Chinese Internet healthcare company Alibaba Health, which was announced today, aims to provide Chinese patients and their families with improved access to healthcare services via a patient-centric health platform. The collaboration will start with a drug tracking platform. Based on the expertise of Merck KGaA, Darmstadt, Germany, in diabetes, thyroid disorders and cardiovascular diseases, the platform will help ensure safety and security of drug use, while generating consistent value for patients through a series of add-on services. With Alibaba Health’s strengths in the field of online healthcare, the two companies will also explore online healthcare service applications, direct-to-patient models as well as Artificial Intelligence- enabled healthcare applications.

Merck KGaA, Darmstadt, Germany, also opened its new OLED Technology Center China in Shanghai today. The new center will provide local customers with customized solutions to enable innovative OLED application development. It offers state-of-the-art equipment and cleanroom facilities for OLED device fabrication and characterization. This location will serve as a collaboration space for customers and Merck KGaA, Darmstadt, Germany, as they work together to generate the ideal solutions for OLED display products. This investment reflects the customer-centric approach of Merck KGaA, Darmstadt, Germany, of developing highly pure, reliable, and efficient OLED materials for innovative products in line with market requirements and in support of customer innovation.

Thirdly, the Life Science business of Merck KGaA, Darmstadt, Germany, today announced a new CRISPR core partnership with Tongji University, Shanghai, China. This is the first partner in China to join leading global scientists from renowned academic institutes including for example Stanford University, USA, in the CRISPR Core Partnership Program of the company. To date, Merck KGaA, Darmstadt, Germany, has more than 70 CRISPR core partners around the world. The program allows dedicated research on treating challenging diseases using genome editing. CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for a variety of medical conditions. CRISPR applications are far-ranging - from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.

The strong commitment of Merck KGaA, Darmstadt, Germany, to China is reflected by today’s new collaboration and investment as well as by the pharmaceutical production plant in Nantong, China, where a new Life Science facility is to be opened early 2019, as announced in late 2016. The overall investment in the second-largest production plant of Merck KGaA, Darmstadt, Germany, after its headquarters in Darmstadt is € 250 million.

Downloads

For more information, contact Gangolf Schrimpf

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Related News

Press Releases

Merck KGaA, Darmstadt, Germany, Awarded Australian CRISPR Nickase Patent for ...

Merck KGaA, Darmstadt, Germany, today announced that the Australian Patent Office has allowed the company’s patent application for the use of paired CRISPR nickases.

2018/08/15

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement